Mattano, Leonard A. Jr http://orcid.org/0000-0002-8409-0589
Devidas, Meenakshi http://orcid.org/0000-0002-1099-3478
Loh, Mignon L. http://orcid.org/0000-0003-4099-4700
Raetz, Elizabeth A.
Chen, Zhiguo
Winick, Naomi J. http://orcid.org/0000-0002-6636-3870
Hunger, Stephen P. http://orcid.org/0000-0002-5492-3957
Carroll, William L. http://orcid.org/0000-0003-1550-4167
Larsen, Eric C.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U10 CA098543, U10 CA180886, U10 CA098413, U10 CA180899)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 4 September 2023
Revised: 6 November 2023
Accepted: 21 November 2023
First Online: 7 December 2023
Competing interests
: LAM has received consulting fees from Novartis and Pfizer, and owns stock in Pfizer. MLL has received consulting fees from Medsix Therapeutics. SPH owns stock in Amgen, and has received honoraria from Amgen and Servier, and consulting fees from Novartis. The other authors declare no competing financial interests.